VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management
American Journal of Hematology · 2024-02 · 99 (2) · 284-299
DOI: 10.1002/ajh.27156 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 11.11.2023. Verfasst von Matthew J Koster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Thrombocytopenia, Hematopoietic Stem Cell Transplantation, Myelodysplastic Syndromes, Skin Diseases, Genetic. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 75 Literaturangaben.
Abstract (Originalsprache)
VEXAS (Vacuoles, E1 enzyme, X‐linked, Autoinflammatory, Somatic) syndrome is a newly identified disease caused by somatic alterations in UBA1 which produce a recalcitrant inflammatory state along with hematologic disturbances. Patients with VEXAS can have a wide spectrum of clinical symptoms and providers should be familiar with the heterogeneity of associated clinical features. While hematologic parameters may be generally non‐specific, peripheral blood features of macrocytosis, monocytopenia, and/or thrombocytopenia coupled with bone marrow vacuolization of erythroid or myeloid precursors should raise suspicion for this condition. Due to an increased mortality, prompt recognition and accurate diagnosis is paramount. Access to testing for confirmation of UBA1 variants is not yet universally available but clinicians should understand the current available options for genetic confirmation of this disease. Treatment options are limited due to lack of prospective clinical trials but cytokine directed therapies such as interleukin‐6 inhibitors and JAK–STAT inhibitors as well as hypomethylating agents such as azacitidine have shown evidence of partial effect. Though cases are limited, allogeneic stem cell transplantation holds promise for durable response and potential cure. The intent of this review is to outline the pathophysiology of VEXAS syndrome and to provide a practical approach to diagnosis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Rheumatology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA.
- Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
ORCID-Profile: Matthew J Koster, Abhishek Mangaonkar, Mrinal M Patnaik
Zitieren
APA
Koster, M. J., Lasho, T. L., Olteanu, H., Reichard, K. K., Mangaonkar, A., Warrington, K. J., & Patnaik, M. M. (2024). VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management. American Journal of Hematology, 99(2), 284-299. https://doi.org/10.1002/ajh.27156
Vancouver
Koster MJ, Lasho TL, Olteanu H, Reichard KK, Mangaonkar A, Warrington KJ, et al. VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management. American Journal of Hematology. 2024;99(2):284-299. doi:10.1002/ajh.27156
BibTeX
@article{Koster2024,
author = {Koster, Matthew J and Lasho, Terra L and Olteanu, Horatiu and Reichard, Kaaren K and Mangaonkar, Abhishek and Warrington, Kenneth J and Patnaik, Mrinal M},
title = {VEXAS syndrome: Clinical, hematologic features and a practical approach to diagnosis and management},
journal = {American Journal of Hematology},
year = {2024},
volume = {99},
number = {2},
pages = {284--299},
doi = {10.1002/ajh.27156}
}
EUVIMED